As illustrated in Figure 3A, serum ZAG might serve as a candidate biomarker for distinguishing the MetS patients from controls with the AUC was 0.655 (95% CI 0.579–0.730, P < 0.001), a sensitivity of 57.6% and a specificity of 70.0%. This evidence concerns the gene AZGP1 and metabolic syndrome.